GlaxoSmithKline now has rights to develop inhaled therapeutics using Liquidia's PRINT particle engineering technology. The development builds on a drug delivery alliance between the two companies that commenced in 2012.
Startup Envisia Therapeutics is presenting the results of its ophthalmology research and technology allowing intracameral drug delivery at the Association for Research in Vision and Ophthalmology 2014 annual meeting in Orlando, FL.
Liquidia Technologies launched a new company this week with $25 million in Series A funding aimed at developing an extended-release glaucoma treatment that could last for several months after one injection.
Liquidia Technologies has spun out a new biotech company in Research Triangle Park, NC, which boasts an early-stage ophthalmology program and $25 million in venture backing from some high-profile investors.
Liquidia Technologies' PRINT platform is a particle-engineering technology that has performed well in two recent studies.
Neal Fowler said a huge market is waiting for nanotech companies; it's just a matter of harnessing the field's potential into practical uses.
Cost is a huge issue in the vaccine industry, especially as companies turn their focus on the developing world. While some groups have looked toward DNA vaccines, virus-like particles (VLPs) and
The Bill and Melinda Gates Foundation, long a staunch supporter of vaccines for children, is putting its money where its mouth is with a $10 million investment in Liquidia Technologies. Xconomy notes
Liquidia Technologies is getting a $10 million boost from the Bill & Melinda Gates Foundation to support its work on next-gen vaccines. Only this time the charitable foundation is taking an
The PATH Malaria Vaccine Initiative (MVI) will have use of Liquidia Technologies' PRINT particle technology for its research into new, more effective malaria vaccines. The technology helps